RESI Europe Innovation Challenge – Meet the Startup Finalists

14 Mar

By Karen Deyo, Investor Research Analyst, LSN

The inaugural RESI Europe is just around the corner, and with that, we are happy to announce the finalists for the RESI Innovation Challenge. On March 25th in Vienna, these finalists will present posters of their technologies in the Exhibition Hall. From therapeutics to devices, diagnostics to digital health, the technologies are as diverse as the countries these companies represent, with startups participating from all over Europe, Israel and even from the US. We encourage all attendees to take the opportunity to check out all of these companies and their technologies and to “invest” your “RESI cash” in your favorite(s). The top three companies will receive prizes at the end of the day, so make sure to go through the exhibition hall and cast your votes!

Thank you to all of the companies that submitted applications to the Innovation Challenge – we encourage you to try again at a future RESI. Good luck to the finalists, and we look forward to seeing you in Vienna!





MedTech Device


Digital Health

Investment Trends in A Well-Funded Space in the Life Sciences: Oncology Innovation Panel at RESI Europe

14 Mar

By Claire Jeong, Director of Research, Asia BD, LSN

claireWhile the life sciences industry is constantly subject to dynamic changes and trends, oncology/Immuno-oncology continues to be one of the most popular areas to invest in. Though some firms shy away from the indication due to it being an overcrowded space, there are many firms who strongly – or even solely focus – on oncology. From relatively traditional modalities such as small molecules (such as the $1B Celgene partnership with Triphase Accelerator/FACIT that happened earlier this year) to rapidly emerging approaches like oncolytic viruses and cell/gene therapy, there are still many promising therapies and novel approaches that have not yet come to light.

The Oncology Innovation panel at the upcoming RESI Europe Conference in Vienna, will highlight 5 speakers who actively seek investment opportunities in oncology. The panel will run from 1:00 – 1:50 pm on the day of RESI Europe, Monday, March 25th, 2019, so if you are a company attending RESI who is working on innovative oncology therapies, you would not want to miss out on this panel.

Here is our lineup of panelists:

Claus Andersson, General Partner, Sunstone Life Science Ventures (Moderator)
Claus Andersson is General Partner in the Life Science group and has been with the team since it was established. He has been engaged with more than 18 companies and has held either chairing positions or board memberships to share his experience from the last 16 years of working with entrepreneurs, co-investors and consultants in life sciences. Claus has extensive experience in strategy execution and technology development from various parts of the Life Science ecosystem: both as an entrepreneur, venture capitalist, scientist, and corporate manager. He holds a Master’s degree in Civil Chemical Engineering from the Technical University of Denmark (DTU) and a PhD in Mathematical Statistics from the University of Copenhagen and the Humboldt University in Berlin.

Toshiyasu Shimomura, Senior Investment Director, Taiho Ventures

Toshi Shimomura is Senior Investment Director at Bay Area-based Taiho Ventures, the corporate venture capital of Taiho Pharmaceutical. With $300M under management, Taiho Ventures invests in early stage oncology companies. Prior to Taiho Ventures, he worked for Taiho Pharmaceutical for 7 years as Early Development Team Chair of TAS-117 (a small molecule AKT inhibitor) being evaluated in Phase I study as well as Biology Project Leader at Taiho’s Tsukuba Research Institute. Before Taiho, he worked for Banyu Pharmaceutical, a subsidiary of Merck & Co. for 10 years. As Project Leader, he developed two clinical development candidates of Aurora A kinase and contributed initiation of Phase I clinical studies. He was also involved other kinase inhibitor programs. He received PhD in Biological Science from Nagoya University, Japan in 1999, where he learned molecular biology, cell cycle and DNA damage checkpoint regulation.

Hakan Goker, Senior Investment Director, M Ventures

Hakan Goker (Ph.D.) is a senior investment director at M Ventures, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan has been investing for the past 12 years and joined Merck Ventures in 2013. Previously Hakan was a partner at Aescap Venture and prior to that worked at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and corporate strategy of multiple biotechnology companies globally including Artios, Asceneuron, Storm, Bicycle, and F-star. Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan currently is a board member at Artios Pharma, Asceneuron, Forendo, Macrophage Pharma, Tocopherx, Synaffix, Storm Therapeutics, Raze Therapeutics and is the chairman of iOnctura.

Mark Krul, Partner, Aglaia Oncology Funds

Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. Before founding Aglaia Oncology Funds in 2004, Mark was Program Director of the NDDO Research Foundation. He held several positions at NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 till 1997 Mark has been Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 till 1993.

Katherine Cohen, Venture Partner, Panacea Venture

Dr. Katherine Cohen is a venture partner at Panacea Venture. From 2011-2016 Dr. Cohen served as CEO at Hookipa Biotech AG (now

Hookipa Pharma Inc), where she led the company founding, Series A and Series B venture financing, and developed the company from early science to clinical stage. Prior to Hookipa, Dr. Cohen served as Senior Vice President for Corporate & Business Development at Intercell AG (now Valneva SE) and participated in the growth of the company from a start up to a successful public/commercial stage enterprise. Prior to her biotech entrepreneurial career, Dr. Cohen worked in academic research and industrial development at Sandoz/VIRCC. Dr. Cohen earned her Ph.D in Biology at the City University of New York and she is a qualified European Patent Attorney.

At RESI Europe, Investors Discuss the Challenges for Diagnostic Startups

14 Mar

By Lucy Parkinson, VP of Investor Research, LSN

There’s a widespread perception that funding and launching new diagnostic technologies is a difficult undertaking.  In addition to the scientific and technical challenges of developing a new product, diagnostic entrepreneurs need to build a solid business case that will indicate future success.  Many fail to realize that investors will be as interested in evidence of market traction and physician support than in signals of diagnostic sensitivity and specificity.

At RESI Europe, five experienced senior staff from investment firms and major strategics in the industry will explain how they look for good bets in the diagnostics field.  Representing a spectrum from early stage investment to potential exit partner, these investors will explain to the audience what it takes to get a diagnostic funded and how they help startups bring new tests and monitoring solutions to market.

Moderator: Tom Miller (Managing Partner, Greybird Ventures)

After receiving a degree in Nuclear Engineering from the University of Massachusetts at Lowell, Tom studied Medical Physics at the Harvard/MIT Health Sciences and Technology joint program graduating with a Masters degree in 1982. During his academic career he worked at Los Alamos, the Swiss Institute for Nuclear Research (now the Paul Scherer Institute), Brookhaven National Laboratory, and the Massachusetts General Hospital as a research associate in radiation biophysics. Tom then joined Siemens Medical Systems where, after 9 years, he became the first non-German CEO of a German factory and business unit. He left Siemens after 15 years to become CEO of the global medical operations of Carl Zeiss. Completing a successful turnaround, he joined Analogic Corporation as CEO. After three years and a doubling of the stock price, Tom left to become CEO of LightLab Imaging, a start-up that he helped to establish. Completing a profitable sale of LightLab, Tom re-joined Siemens eventually serving as a member of the operating board of Siemens Healthcare and the CEO of Customer Solutions Division, responsible for 26,000 employees in over 130 countries. Tom co-founded GreyBird in mid-2013 with an investment focus on technologies enabling precision medicine diagnosis.

Walter Stockinger (Managing Partner, Hadean Ventures)

Walter is a seasoned healthcare investor with previous experience in strategy consulting and basic research. After joining the Boston Consulting Group as a member of the Healthcare Practice Team Walter advised pharmaceutical companies and PE firms in the context of commercial projects as well as during buy and sell side M&A transactions. In 2009 walter joined the London office of one of the largest specialist healthcare VC firms. Being responsible for deal sourcing, due diligence and exit management Walter gained significant experience by successfully investing into and exiting portfolio companies.

Walter received a master’s degree and a PhD in biochemistry from the University of Vienna. After his graduation, he worked for over five years as a research fellow at Harvard University. He has published 15 peer reviewed papers in top scientific journals including Cell and EMBO.

Michael Sidler (General Partner, Redalpine)

Dr. Michael Sidler has co-founded Redalpine Venture Partners 2007 and acts as General Partner for Redalpine Capital Funds I to IV. Redalpine invests in European tech and health tech companies. Before Redalpine, Michael was responsible for corporate investments and M&A at Prionics AG, a Diagnostics / Biotech company in, Switzerland, where under his guidance several acquisitions have been completed. From 1998 to 2003, Michael was with The Boston Consulting Group in Zürich and Toronto. Michael Sidler holds a PhD in Life Sciences from University of Zurich. He is a member of several organizations, juries and boards for the support of innovation and startups.

Ekkehard Kauffmann (Global Business Development M&A, Roche Diagnostics)

M&A and Strategy lead in Roche Diagnostic Global Business Development, responsible for external growth strategies as well as evaluating and securing early to commercial stage innovation for Roche Diagnostics through acquisitions and other deal types. Previous leadership roles in business development and R&D at Bayer and in the Novartis spin-off company Zeptosens. Ph.D. in Biophysics and executive MBA education background.

%d bloggers like this: